NanoViricides, Inc. Announces US FDA has Confirmed Pre-IND Meeting Date
Published: Mar 05, 2012
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company’s scientists. This pre-IND meeting will focus on FluCide™, designated as NV-INF-1, the Company’s novel anti-influenza drug.